Recruiting Trials

Age ≥ 18
Have chronic heart failure with reduced ejection fraction

Age ≥ 18
Fasting triglyceride level ≥10 mmol/L
Diagnosed with familial chylomicronemia syndrome

Age 16 - 80
Diagnosed with eosinophilic esophagitis by eophagogastroduodenoscopy (EGD) and esophageal biopsy
Have symptomatic eosinophilic esophagitis

Age ≥ 18
Chronic hepatitis B infection

Age 18 - 65
Chronic hepatitis B infection
On stable NUC therapy (e.g. entecavir or tenofovir)

Age 18 - 65
Chronic hepatitis B infection
On stable NUC therapy (e.g. entecavir or tenofovir alafenamide/disoproxil fumarate)

Age ≥ 18
Diagnosed follicular lymphoma

Age ≥ 18
Diagnosed with relapsed or refractory multiple myeloma
No long-term use of prednisone

Age ≥ 18
Newly diagnosed multiple myeloma
Ineligible for autologous stem cell transplant
No prior treatment for multiple myeloma except localised radiotherapy or a short course of steroids

Age ≥ 18
Diagnosed with myelodysplastic syndrome (MDS)
Has anemia

Age ≥ 18
Diagnosed primary or secondary myelofibrosis
Has splenomegaly

Staphylococcus aureus bloodstream infection
Admitted to hospital

Age ≥ 60
History of urinary tract infection in past 2 years

Age ≥ 18
Admitted to an acute-care hospital
Confirmed SARS-CoV-2 by nucleic acid testing in the 14 days prior to randomisation

Advanced colorectal adenoma at first colonoscopy in the National Bowel Screening Programme
No residual colorectal adenomas
Next colonoscopy planned within 5 years

Indigenous (Australian Aboriginal and/or Torres Strait Islander; or New Zealander Maori and/or Pacific Islander)
Hospitalised with an ALRI (bronchiolitis or pneumonia)
Required oxygen or respiratory support at any point of illness (including transfer and in the community) OR fluid support (NG or IV) OR recurrent admission within 3 months
Aged ≥ 3 months

Age ≥ 18
Be undergoing a surgical procedure resulting in a closed approximately linear incision

Age ≥ 45 or ≥ 18 years with diabetes
ESKD treated with haemodialysis, or peritoneal dialysis, for at
least 3 months
Prescribed at least one phosphate-lowering medication at any
dose

Age ≥ 18
Diagnosed with IgA Nephropathy
On a stable dose of an ACE inhibitor or ARB/unable to tolerate this therapy

Age > 12
Diagnosed and confirmed with asthma
Have had asthma for at least 1 year
Evidence of past or current atopy

Age 18 - 85
diagnosed non-cystic fibrosis bronchiectasis, two or more exacerbations in the past 12 months

Age 40 - 90
Confirmed COPD diagnosis
Have a history of frequent exacerbations (2 or more exacerbation in a 12 month period)

Age ≥ 18
Confirmed diagnosis of bronchiectasis within 5 years
Pulmonary exacerbation requiring antibiotics in the past 12 months

Age 18 - 75
Diagnosed systemic lupus erythematosus (SLE)
Must be receiving one or more standard therapies for SLE at a stable dose

Age > 18
Acute tetraplegic patients